RP2 and leukemia: In conclusion, we have shown that RP2 inhibitors effectively target both KG1a cells enriched for dormancy by mTOR inhibition and CD71neg primary leukaemia patient samples thus providing grounds for suggesting that transcriptional RP2 inhibitors may be a useful class of agent for targeting dormant cells thought to contribute to relapses in leukaemia.